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ABSTRACT
Prediction of peptide binding to major histocom-
patibility complex (MHC) molecules is a basis for
anticipating T-cell epitopes, as well as epitope
discovery-drivenvaccinedevelopment.Inthehuman,
MHC molecules are known as human leukocyte
antigens (HLAs) and are extremely polymorphic.
HLA polymorphism is the basis of differential
peptide binding, until now limiting the practical use
of current epitope-prediction tools for vaccine devel-
opment. Here, we describe a web server, PEPVAC
(Promiscuous EPitope-based VACcine), optimized
for the formulation of multi-epitope vaccines with
broad population coverage. This optimization is
accomplished through the prediction of peptides
that bind to several HLA molecules with similar
peptide-binding specificity (supertypes). Specifically,
we offer the possibility of identifying promiscuous
peptide binders to five distinct HLA class I super-
types (A2, A3, B7, A24 and B15). We estimated the
phenotypic population frequency of these super-
types to be 95%, regardless of ethnicity. Targeting
these supertypes for promiscuous peptide-binding
predictions results in a limited number of potential
epitopes without compromising the population
coverage required for practical vaccine design con-
siderations. PEPVAC can also identify conserved
MHC ligands, as well as those with a C-terminus
resulting from proteasomal cleavage. The combina-
tion of these features with the prediction of promis-
cuous HLA class I ligands further limits the number
of potential epitopes. The PEPVAC server is hosted
by the Dana-Farber Cancer Institute at the site http://
immunax.dfci.harvard.edu/PEPVAC/.
INTRODUCTION
T-cells are the key component of the adaptive immune system,
playing a pivotal role ﬁghting both infectious agents and can-
cer cells (1). T-cell-based immune responses are driven by
antigenic peptides (epitopes), presented in the context of
major histocompatibility complex (MHC) molecules (2).
Therefore, the prediction of peptides that can bind to MHC
molecules has become the basis for the anticipation of T-cell
epitopes (3). MHC molecules fall into two major classes,
namely MHC class I (MHCI) and MHC class II (MHCII).
Antigens presented by MHCI and MHCII are recognized by
two distinct sets of T-cells, CD8
+ T and CD4
+ T-cells, respect-
ively. Identiﬁcation of T-cell epitopes is important for both
understanding disease pathogenesis and vaccine design. Thus,
the availability of computational methods that can readily
identify potential epitopes from primary protein sequences
has fueled a new paradigm in vaccine development that is
driven by this epitope discovery.
Amajor complicationtothisvaccine development approach
is the extreme polymorphism of the MHC molecules. In the
human, MHC molecules are known as human leukocyte anti-
gens (HLAs), and there are hundreds of allelic variants of the
class I (HLA I) and the class II (HLA II) molecules. These
HLA allelic variants bind distinct sets of peptides as MHC
polymorphism is the basis for peptide-binding speciﬁcity
(4), and are expressed at vastly variable frequencies in
different ethnic groups (5). This complexity suggests that a
large number of HLA molecules will have to be targeted
for peptide-binding predictions, requiring so many peptides
to elicit a broadly protective multi-epitope vaccine as to be
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(supertypes) can bind largely overlapping sets of peptides
(6,7).TheidentiﬁcationoftheseHLAsupertypesfacilitatesthe
epitope-based vaccine development for the following two
reasons: ﬁrst, targeting of representative HLA alleles from
distinct supertypes allows the immune response to be stimu-
lated in a variety of genetic backgrounds; second, the selection
of promiscuous peptide binders to those alleles included
within a given supertype limits the number of peptides to




miscuous epitopes to ﬁve HLA I supertypes: A2 (A*0201-07,
A*0209andA*6802),A3(A*0301,A*1101,A*3101,A*3301,
A*6801andA*6601),A24(A*2402andB*3801),B7(B*0702,
B*3501, B*5101-02, B*5301 and B*5401) and B15 (A*0101,
B*1501_B62andB1502).Thesesupertypesweredeﬁnedusing
a method based on the clustering of the predicted peptide-
bindingrepertoireofMHCmolecules(8).Thecombinedpheno-
typic frequency of these supertypes is >95% for ﬁve major
American ethnicities (Black, Caucasian, Hispanic, Native
American and Asian). Thus, targeting these supertypes with
epitopepredictionswouldpotentiallyprovideapopulationcov-
erage >95%, regardless of ethnicity.
Peptides binding to HLA I molecules are potential CD8
+
T-cell epitopes. In vivo, the C-terminus of these antigenic
epitopes results from the selective proteolysis of cytosolic
proteins mediated by the proteasome (9). The proteasome is
thusimportantfordeterminingtheseepitopes.Therefore,PEP-
VAC has also been implemented with an algorithm for the
identiﬁcation of those peptides containing a C-terminus that is
likely to be the result of proteasomal cleavage. Finally, PEP-
VAC also allows the prediction of conserved epitopes from
sequences with variability masked. The combination of these
two features serves in both reﬁning the predictions of T-cell
epitopes and limiting the number of potential epitopes.
Prediction of peptide-MHCI binding
The peptide-binding mode of MHCI molecules differs from
that of MHCII (10–12), and as result, the prediction of
peptide-MHCII binding is less reliable than that of peptide-
MHCI binding. Thereby, we have focused here in the predic-
tion of MHCI ligands, a class that is speciﬁcally recognized by
CD8
+ cytotoxic T lymphocytes. Peptides binding to a speciﬁc
MHCI molecule are related by sequence similarity, and thus
we use position-speciﬁc scoring matrix (PSSM) from aligned
MHCI ligands as the predictors of peptide-MHCI binding in
combination with a dynamic algorithm. PSSMs are also
known as proﬁles and weight matrices and have previously
been shown to be adequate tools for the prediction of peptide-
MHC binding (13–16). PSSMs are derived from block align-
ments of MHCI ligands that are of the same length. Such a
restriction guarantees proper structural alignment of ligands
and subsequent accuracy of the peptide-binding predictions
(13,14). Given that MHCI-ligands are usually of nine residues
in length, PSSMs used in this study are for the prediction of
ligands of that same size (nine residues). Accuracy of the
prediction of peptide-MHCI binding using PSSMs varies
depending on threshold and the targeted MHCI molecule.
On average, however, ROC analyses of the predictions at
different thresholds result in AUC values (Area Under ROC
Curve) above 0.8, indicating that these PSSMs are very good
for predictors of peptide-MHCI binding. Furthermore, >80%
of known CD8
+ T-cell epitopes can be predicted at a 2%
threshold from their protein sources.
Supertypes: identification and population coverage
analysis
We deﬁned HLA I supertypes through clustering of predicted
MHC peptide-binding repertoires (8). In brief, the core of the
method consists of the generation of a distance matrix whose
coefﬁcients are inversely proportional to the peptide binders
shared by any two HLA molecules (Figure 1). Subsequently,
this distance matrix is fed to a phylogenic clustering algorithm
to establish the kinship among the distinct HLA peptide-
binding repertoires. Figure 2 shows a phylogenic tree built
upon the peptide-binding repertoire of 55 HLA I molecules,
using a Fitch and Margoliash clustering algorithm (17). We
deﬁned supertypes (Figure 2) as groups of HLA I alleles with
>20% peptide-binding overlap (pairwise between any pair of
alleles). The supertypes identiﬁed in this study include the A2,
A3, B7, B27 and B44 supertypes previously identiﬁed by
Sidney et al. (16). Furthermore, we have also identiﬁed
three new supertypes, BX, B15 and B57 (Figure 2). The cumu-
lativephenotypicfrequency(CPF)ofthesesupertypesisshown
in Table 1. CPF was calculated using the gene and haplotype
frequencies reported for ﬁve distinct American ethnic groups
including Blacks, Caucasians, Hispanic, North American
Figure 1. StrategytodefineHLAIsupertypes.HLAIsupertypesareidentified
by clustering their peptide-binding repertoire (8). The method consists of four
basic steps. (i) Predict the peptide-binding repertoire (i,j sets in figure) of each
HLA I molecule from the same random protein using the relevant PSSMs in
combination with the RANKPEP scoring algorithm (13). (ii) Compute the
number of common peptides between the binding repertoire of any two
HLAI molecules.(iii)Builda distancematrix whosecoefficientsare inversely
proportional to the peptide-binding overlap between any pair of HLA I
molecules.(iv)Useaphylogenicclusteringalgorithmtocomputeandvisualize
HLA I supertypes (clusters of HLA I molecules with overlapping peptide-
binding repertoires).
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erage that would be provided by a vaccine composed of epi-
topes restricted by the alleles included in the supertype. The
A2, A3 and B7 supertypes have the largest CPF in the ﬁve
studied ethnic groups, close to 90%, irrespective of ethnicity.
To increase the population coverage to >95%, regardless of
ethnicity, it is necessary to include at least two more super-
types. Speciﬁcally, the supertypes A2, A3, B7, B15 and A24/
B44 represent the minimal supertypic combinations with the
indicated population coverage. Alleles belonging to each of
these supertypes are shown in Figure 2 and Table 1.
PEPVAC web server
FollowingtheHLA Isupertypicanalysisasdiscussed,wehave
implemented a tool for the prediction of promiscuous peptide
binders to a set of supertypes with a CPF >95%, irrespective of
ethnicity. We named this tool PEPVAC, and it is Online at the
Figure 2. HLA I peptide-binding overlap and supertypes. The Figure shows an unroot dendrogram built after clustering the overlap between the peptide-binding
repertoire of the indicated HLA I molecules. Peptide-binding repertoires of HLA I molecules were obtained from a random protein (1000 amino acids) using the
relevant PSSMs at a 2% peptide-binding threshold. This dendrogram reflects the relationship between the peptide-binding specificities of HLA I molecules. HLA I
alleleswithsimilarpeptide-bindingspecificitiesbranchtogetheringroupsorclusters.ThecloserHLAIallelesbranch,thelargeristheoverlapbetweentheirpeptide-
bindingrepertoires.Supertypes(shadowedwithdifferent colors)consistof groupsHLAI alleleswithat leasta 20%peptide-bindingoverlap(pairwisebetweenany
pair of alleles).
Table 1. Cumulative phenotype frequency of defined supertypes
Supertype Alleles Blacks (%) Caucasians (%) Hispanics (%) North American natives (%) Asians (%)
A2 A*0201-7, A*6802 43.7 49.9 51.8 52.4 44.7
A3 A*0301, A*1101, A*3101,
A*3301, A*6801, A*6601
35.4 46.9 41.5 40.7 47.9
B7 B*0702, B*3501, B*5101-02,
B*5301, B*5401
45.9 42.2 40.5 52.0 31.3
B15 A*0101, B*1501_B62, B1502 13.06 37.80 16.75 27.26 21.04
A24 A*2402, B*3801 15.5 17.28 25.85 41.94 35.0
B44 B*4402, B*4403 10.4 27.7 17.15 14.4 10.1
B57 B5701-02, B5801, B*1503 19.2 10.3 5.9 5.8 16.5
ABX A*2902, B*4002 7.4 11.3 19.1 16.3 16.3
B27 B*2701-06, B*2709, B*3909 2.3 4.8 5.1 16.9 4.7
BX B*1509, B*1510, B*39011 3.1 0.7 4.2 7.8 4.1
Cumulative phenotype frequency was obtained using the HLA I gene and haplotype frequencies published by Cao et al. (18) corresponding to the indicated five
Americanethnicgroups.MethodforcomputingthecumulativephenotypefrequencyconsideredthedisequilibriumlinkagebetweentheHLA-Aand-Bgeneandwas
based on that reported by Dawson et al. (21).
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Molecular Immunology Foundation/Dana-Farber Cancer
Institute. The web interface to PEPVAC is divided into several
sections that facilitate intuitive use (Figure 3A). Main features
of the web server are discussed bellow.
Input and limitations. In PEPVAC, input query to carry epi-
tope predictions is entered in the GENOME section
(Figure 3A). Input consists of a single or various protein
sequences in FASTA format. Only the standard 20 amino
acid residues are considered. There are several translated gen-
omes from pathogenic organisms that can be selected as
inputs. More useful, a user-provided local ﬁle containing a
setofproteinsequences canbeuploaded totheserver usingthe
choose/browse bottom. PEPVAC can also process ﬁles with
protein sequences, in which the variable sites have been
masked with a dot ‘.’ symbol. In that case, peptide-binding
predictions will be carried out only over consecutive stretches
of nine or more residues. Sequences with variable positions
masked according to the Shannon entropy variability metric
(4,19) can be obtained at the site http://immunax.dfci.harvar-
d.edu/bioinformatics/Tools/sva.html.Currently,thereisalimit
of200sequences and50000symbolsthatcanbeprocessedper
request. If such limits are exceeded, the server will return an
error.
Supertypes and thresholds. The A2, A3, B7, B15 and A24
(Figure 2 and Table 1) supertypes have been chosen for pro-
miscuous peptide-binding predictions in PEPVAC. Only those
peptides that are predicted to bind to all the alleles included in
the supertypes are returned in the output (Figure 3B). Thresh-
old for the prediction of promiscuous peptide binders in PEP-
VAC has been ﬁxed to provide a reduced and manageable set
of promiscuous peptide binders to each supertype. As an
example, predicted promiscuous peptides to the above ﬁve
supertypes from a genome, such as that of Inﬂuenza virus A
(4160 amino acids) distributed in 10 distinct open reading
frames, represent only 5.51% (254 9mer peptides) of all pos-
sible peptides (4617 9mer peptides).
Proteasome cleavage. In PEPVAC, predictions of supertypic
peptide binders are combined with the prediction of pro-
teasomal cleavage using probabilistic language models
derived from HLA I-restricted epitopes (14). Currently,
there are three optional models for proteasomal cleavage
Figure 3. The PEPVAC web server. (A) PEPVAC input page. The page is divided into several sections. E-MAIL, for obtaining the results via e-mail (optional).
GENOMES,where a selectionofgenomesfrompathogenicorganismsis available,aswell asthe possibilityofuploadinga user-providedgenome.SUPERTYPES,
the supertypes A2, A3, B7, A24, and B15 are available for selection. Alleles targeted for peptide-biding predictions in each supertype are indicated. The minimum
populationcoverageoftheselectedsupertypesiscalculatedontheflyandshownontherelevantwindow.PROTEASOMALCLEAVAGE,predictionofproteasomal
cleavage using three optimal language models is carried out in parallel to the peptide-biding predictions. (B) PEPVAC result page. An example result page where
theA3supertypewasselectedforpeptide-bindingpredictionsfromthegenomeofInfluenzaAvirus(A/PR/8/34)isshown.Theresultpagefirstdisplaysasummaryof
thepredictions,followedbythepredictedpeptidebinderstoeachoftheselectedsupertypes(onlyA3intheshownexample).Peptideshighlightedinvioletcontaina
C-terminal residue that is predicted to be the result of proteasomal cleavage. If the proteasomal cleavage filter is checked ON in the input page, only violet peptides
will be shown.
Nucleic Acids Research, 2005, Vol. 33, Web Server issue W141that differ in their sensitivity/speciﬁcity ratio of the predictions
as discussed elsewhere (14). These models are selected within
the PROTEASOME CLEAVAGE section. Model 1 has the
highest sensitivity (95%) and the lower speciﬁcity (60%).
Conversely, Model 3 has the lowest sensitivity (65%) with the
largest speciﬁcity (80%). Model 2 has a sensitivity and spe-
ciﬁcity of 70%. Promiscuous peptide binders containing a C-
terminal end, predicted to be the result of proteasomal cleav-
age, are shown in violet in the result page (Figure 3B). In the
previous example with the Inﬂuenza virus A, the list of pro-
miscuous peptide binders to the ﬁve selected supertypes
decreases from 254 down to 170 peptides (3.7% of all 9mer
peptides from Inﬂuenza virus A genome) after considering
proteasomalcleavage usingModel 1. Furthermore, a combina-
tion of the predictions of peptide-MHCI binding and proteaso-
malcleavageincreasesthespeciﬁcityoftheepitopepredictions
by discarding predicted peptide-MHCI binders that are experi-
mentally unable to elicit CD8
+ T-cell responses (20).
Output. The results page returned by PEPVAC is shown in
Figure 3B. This page ﬁrst displays a summary of the predic-
tions, including the chosen selections, the number of predicted
peptides and the minimum population coverage provided by
the supertypic selection, followed by the predicted peptide
binders to each of the selected supertypes (only A3 in the
shown example). Peptides are predicted to bind to all alleles
included in the supertype, and appear ranked with regard to the
PSSMs of the ﬁrst allele included in the supertype. Relevant
information about each sorted peptide includes its protein
source as well as its molecular weight.
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